Empowered Patient Podcast

Dr. John Krakauer is the Chief Medical Advisor at MindMaze, pioneers in digital neurotherapeutics focused on brain health and recovery from neurological diseases and injuries.

John explains, "What we really mean by digital neurotherapeutics is the belief that one can actually administer a medicine in a way that's different from pharmacology, different from surgery or devices. But in fact, consider software as a pill so that you can actually have a software experience, an immersive gaming-like experience that can actually have an effect on a disease, in particular, neurological conditions in a way comparable to other medical approaches."

"So MindMaze really would like to create immersive gaming software that allows the nervous system after injury or disease to undergo such change. We're different, I think, in so much that we realize that you can't just be an app on a phone or a tablet. You have to be in an immersive full-body experience that combines exercise, cognitive challenge, and skill learning. And so, we're creating that kind of digital therapeutic experience."

@MindMazeTech #ImmersiveTherapy #NeurologicalDiseases #NeurologicalInjuries #DigitalHealth

MindMaze.com

Listen to the podcast here

Tim Clackson is the President and CEO of Theseus Pharmaceuticals which has a mission to outsmart cancer resistance by developing pan-variant tyrosine kinase inhibitors (TKIs) that are designed to hit different types of cancer cell mutations. The goals of the therapy are to delay treatment resistant cancer as well as effectively deal with the variety of cancer mutations once they have occurred.

Tim explains, "The unfortunate truth is that nearly all types of tumors at some point are going to develop resistance. We are at this stage now where some tumors that are caught early can be really cured and go into long-term remission. Still, there's a substantial portion of tumor types and certainly those that are caught a little bit later that unfortunately show an almost inevitable evolution of resistance. So, then the challenge becomes, can you delay how long that resistance takes to emerge? And then can you come up with therapies or approaches that will hopefully substantially prolong the post resistance treatment with a different therapy?"

"So kinase is a name for a family of proteins that often goes bad in cancer. Often the mutations are in kinases, and our approach is really to develop what are called kinase inhibitors, tyrosine kinase inhibitors or TKIs. There are many TKIs already developed, but we believe that it's really important to develop a particular kind that we call a pan-variant inhibitor. So that is a molecule that is designed to hit any of the different flavors of resistance cancer that you can find in a patient. Unfortunately, one of the biggest problems in cancer treatment, especially when you have a cancer with a particular driver, is that you find multiple different types of resistance in the same patient."

@ThereusRX #GastrointestinalStromalTumors #GIST #Cancer #Oncology

Theseusrx.com

Listen to the podcast here

Tim Clackson is the President and CEO of Theseus Pharmaceuticals which has a mission to outsmart cancer resistance by developing pan-variant tyrosine kinase inhibitors (TKIs) that are designed to hit different types of cancer cell mutations. The goals of the therapy are to delay treatment resistant cancer as well as effectively deal with the variety of cancer mutations once they have occurred.

Tim explains, "The unfortunate truth is that nearly all types of tumors at some point are going to develop resistance. We are at this stage now where some tumors that are caught early can be really cured and go into long-term remission. Still, there's a substantial portion of tumor types and certainly those that are caught a little bit later that unfortunately show an almost inevitable evolution of resistance. So, then the challenge becomes, can you delay how long that resistance takes to emerge? And then can you come up with therapies or approaches that will hopefully substantially prolong the post resistance treatment with a different therapy?"

"So kinase is a name for a family of proteins that often goes bad in cancer. Often the mutations are in kinases, and our approach is really to develop what are called kinase inhibitors, tyrosine kinase inhibitors or TKIs. There are many TKIs already developed, but we believe that it's really important to develop a particular kind that we call a pan-variant inhibitor. So that is a molecule that is designed to hit any of the different flavors of resistance cancer that you can find in a patient. Unfortunately, one of the biggest problems in cancer treatment, especially when you have a cancer with a particular driver, is that you find multiple different types of resistance in the same patient."

@ThereusRX #GastrointestinalStromalTumors #GIST #Cancer #Oncology

Theseusrx.com

Download the transcript here

Dr. John Krakauer is the Chief Medical Advisor at MindMaze, pioneers in digital neurotherapeutics focused on brain health and recovery from neurological diseases and injuries.

John explains, "What we really mean by digital neurotherapeutics is the belief that one can actually administer a medicine in a way that's different from pharmacology, different from surgery or devices. But in fact, consider software as a pill so that you can actually have a software experience, an immersive gaming-like experience that can actually have an effect on a disease, in particular, neurological conditions in a way comparable to other medical approaches."

"So MindMaze really would like to create immersive gaming software that allows the nervous system after injury or disease to undergo such change. We're different, I think, in so much that we realize that you can't just be an app on a phone or a tablet. You have to be in an immersive full-body experience that combines exercise, cognitive challenge, and skill learning. And so, we're creating that kind of digital therapeutic experience."

@MindMazeTech #ImmersiveTherapy #NeurologicalDiseases #NeurologicalInjuries #DigitalHealth

MindMaze.com

Download the transcript here

Emee Baldwin, Founder of Poppy's Purpose, is a nursing student and patient advocate with a success story about getting the attention of care providers and elected officials to re-evaluate the rules regarding patient visitation rights, particularly in the age of COVID-19. Emee and her family worked with their local representatives to make a law in Alabama where no patient will be alone every day.

Emee elaborates, "So, last November, November of 2020, my grandfather, known to me as Poppy, was diagnosed with COVID-19. This was new to us, and it was new to everyone at the time. But to start with the background story, I was used to seeing my Poppy every single day. I grew up on a small family farm, so we were very close. If I didn't see him every day, I at least heard from him every day, so when he was first admitted to the hospital with COVID-19, that first week, he was just on a regular floor up here in Huntsville, Alabama, which is where I live and where I go to school. So it was really odd being two miles away from him and not being able to get in to see him."

"Ultimately, he ended up passing away after a little over three weeks, and he was in the hospital just a little over three weeks, completely by himself. My grandfather was very involved in politics here in Alabama, so at his funeral, we had a lot of politicians there, a lot of legislators there. Right after the service was over, they came up to us, and they were like, "We've seen the hurt that your family went through. We saw it firsthand through you, and we want to make a change. We want to help y'all to overcome this. That way, other families don't have to battle what you went through."

@Emee_Elizabeth #PatientAdvocate #COVID #COVID19 #PatientRights

poppyspurpose.org

Listen to the podcast here

Emee Baldwin, Founder of Poppy's Purpose, is a nursing student and patient advocate with a success story about getting the attention of care providers and elected officials to re-evaluate the rules regarding patient visitation rights, particularly in the age of COVID-19. Emee and her family worked with their local representatives to make a law in Alabama where no patient will be alone every day.

Emee elaborates, "So, last November, November of 2020, my grandfather, known to me as Poppy, was diagnosed with COVID-19. This was new to us, and it was new to everyone at the time. But to start with the background story, I was used to seeing my Poppy every single day. I grew up on a small family farm, so we were very close. If I didn't see him every day, I at least heard from him every day, so when he was first admitted to the hospital with COVID-19, that first week, he was just on a regular floor up here in Huntsville, Alabama, which is where I live and where I go to school. So it was really odd being two miles away from him and not being able to get in to see him."

"Ultimately, he ended up passing away after a little over three weeks, and he was in the hospital just a little over three weeks, completely by himself. My grandfather was very involved in politics here in Alabama, so at his funeral, we had a lot of politicians there, a lot of legislators there. Right after the service was over, they came up to us, and they were like, "We've seen the hurt that your family went through. We saw it firsthand through you, and we want to make a change. We want to help y'all to overcome this. That way, other families don't have to battle what you went through."

@Emee_Elizabeth #PatientAdvocate #COVID #COVID19 #PatientRights

poppyspurpose.org

Download the transcript here

Hamid Khoja is the Chief Scientific Officer of FibroBiologics which is developing regenerative medicine using fibroblasts which are one of the most abundant cells in the human body. While stem cell therapy has gotten significant attention, fibroblasts are easier to source and grow.

Hamid elaborates, "Just to give you a sense of some of the capabilities of fibroblasts. They behave very similarly in many aspects to stem cells, which we're very well aware of. What makes fibroblasts significantly interesting for us and for therapeutic purposes is that they can also differentiate into many different cell types."

"So the CybroCell is the product name that we've given our tolerogenic fibroblasts, cells that have been specifically cultured for use in degenerative disc disease. But we've also tested this same product in a clinical trial for multiple sclerosis. So we have done limited trials for safety for both degenerative disc disease and multiple sclerosis, and the results have been very promising."

#FibroBiologics #Fibroblasts #DegenerativeDiscDisease #DDD #MultipleSclerosis #MS #MultipleSclerosisTreatment #StemCellAlternative

FibroBiologics.com

Listen to the podcast here

Hamid Khoja is the Chief Scientific Officer of FibroBiologics which is developing regenerative medicine using fibroblasts which are one of the most abundant cells in the human body. While stem cell therapy has gotten significant attention, fibroblasts are easier to source and grow.

Hamid elaborates, "Just to give you a sense of some of the capabilities of fibroblasts. They behave very similarly in many aspects to stem cells, which we're very well aware of. What makes fibroblasts significantly interesting for us and for therapeutic purposes is that they can also differentiate into many different cell types."

"So the CybroCell is the product name that we've given our tolerogenic fibroblasts, cells that have been specifically cultured for use in degenerative disc disease. But we've also tested this same product in a clinical trial for multiple sclerosis. So we have done limited trials for safety for both degenerative disc disease and multiple sclerosis, and the results have been very promising."

#FibroBiologics #Fibroblasts #DegenerativeDiscDisease #DDD #MultipleSclerosis #MS #MultipleSclerosisTreatment #StemCellAlternative

FibroBiologics.com

Download the transcript here

Scott Gray is the President and CEO of Clincierge with a mission to support participants in clinical trials, particularly for patients with rare diseases. Since many rare diseases require a patient caregiver to accompany a trial participant, Clincierge also manages the logistics for both of those people. The result of these patient-centric efforts is greater diversity in recruitment, higher retention rates, and higher participant satisfaction.

Scott explains, "The purpose for Clincierge is to improve clinical trial performance by improving the patient experience. Depending upon the disease state, different patients require different types of support to enable them to participate in a clinical trial. It may be a geographic location for a family so that a pediatric patient can participate in a trial. It may be language barriers, so we provide interpreters. Along with that relocation may come the need for housing that's funded, prepaid, meal stipends, ground transportation, visa services."

"So what we do is look at each individual patient's need and design the services that support them, enable them to get to the clinical trial visits so that they can participate, and the research team can get their outcomes data."

@Clincierge #Clincierge #RareDisease #RareDiseaseDay #RareDiseaseMonth #ClinicalTrials #ClinicalTrialResearch #PatientCentricity #PatientEngagement #PatientExperience #PTEXP

Clincierge.com

Listen to the podcast here

Scott Gray is the President and CEO of Clincierge with a mission to support participants in clinical trials, particularly for patients with rare diseases. Since many rare diseases require a patient caregiver to accompany a trial participant, Clincierge also manages the logistics for both of those people. The result of these patient-centric efforts is greater diversity in recruitment, higher retention rates, and higher participant satisfaction.

Scott explains, "The purpose for Clincierge is to improve clinical trial performance by improving the patient experience. Depending upon the disease state, different patients require different types of support to enable them to participate in a clinical trial. It may be a geographic location for a family so that a pediatric patient can participate in a trial. It may be language barriers, so we provide interpreters. Along with that relocation may come the need for housing that's funded, prepaid, meal stipends, ground transportation, visa services."

"So what we do is look at each individual patient's need and design the services that support them, enable them to get to the clinical trial visits so that they can participate, and the research team can get their outcomes data."

@Clincierge #Clincierge #RareDisease #RareDiseaseDay #RareDiseaseMonth #ClinicalTrials #ClinicalTrialResearch #PatientCentricity #PatientEngagement #PatientExperience #PTEXP

Clincierge.com

Download the transcript here